Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma

Journal of Clinical Oncology

Volumn 29, Issue 34, 2011, Pages 4534-4540

  Juergens, Heribert ^a   Daw, Najat C ^b,c   Geoerger, Birgit ^d   Ferrari, Stefano ^f   Villarroel, Milena ^g   Aerts, Isabelle ^e   Whelan, Jeremy ^h   Dirksen, Uta ^a   Hixon, Mary L ⁱ   Yin, Donghua ^j   Wang, Tao ^j   Green, Stephanie ^j   Paccagnella, Luisa ^j   Gualberto, Antonio ^i,j  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e INSTITUT CURIE   (France)

^f RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^g HOSPITAL LUIS CALVO MACKENNA   (Chile)

^h UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

ⁱ BROWN UNIVERSITY   (United States)

^j PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIGITUMUMAB; SOMATOMEDIN C;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EWING SARCOMA; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NAUSEA; OCULAR HYPEREMIA; OSTEOSARCOMA; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR, IGF TYPE 1; RECURRENCE; RETREATMENT; SARCOMA, EWING;

EID: 80053062871     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.0670     Document Type: Article

References (22)

1. Helman LJ, Meltzer P: Mechanisms of sarcoma development. Nat Rev Cancer 3:685-694, 2003 (Pubitemid 37328823)
2. Fletcher CDM, Unni KK, Mertens F: World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France, IARC Press, 2002
3. Prieur A, Tirode F, Cohen P, et al: EWS/FLI-1 silencing and geneprofiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24:7275-7283, 2004 (Pubitemid 39014452)
4. Toretsky JA, Kalebic T, Blakesley V, et al: The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 272:30822-30827, 1997 (Pubitemid 27527522)
5. Olmos D, Tan DS, Jones RL, et al: Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: Twenty years from the bench to the bedside. Cancer J 16:183-194, 2010
6. Gualberto A: Figitumumab (CP-751,871) for cancer therapy. Expert Opin Biol Ther 10:575-585, 2010
7. Olmos D, Postel-Vinay S, Molife LR, et al: Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: A phase 1 expansion cohort study. Lancet Oncol 11:129-135, 2010
8. Kurmasheva RT, Dudkin L, Billups C, et al: The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 69:7662-7671, 2009
9. Lacy MQ, Alsina M, Fonseca R, et al: Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 26:3196-3203, 2008
10. Haluska P, Shaw HM, Batzel GN, et al: Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13:5834-5840, 2007 (Pubitemid 47583908)
11. Bhatia S, Krailo MD, Chen Z, et al: Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood 109:46-51, 2007 (Pubitemid 46053041)
12. Rihani R, Bazzeh F, Faqih N, et al: Secondary hematopoietic malignancies in survivors of childhood cancer: An analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry. Cancer 116:4385-4394, 2010
13. Friedman DL, Whitton J, Leisenring W, et al: Subsequent neoplasms in 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 102:1083-1095, 2010
14. Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, et al: Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: Pooled individual data analysis of 17 prospective studies. Lancet Oncol 11:530-542, 2010
15. Pollak M: Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 8:915-928, 2008
16. Major JM, Laughlin GA, Kritz-Silverstein D, et al: Insulin-like growth factor-I and cancer mortality in older men. J Clin Endocrinol Metab 95:1054-1059, 2010
17. Juul A, Flyvbjerg A, Frystyk J, et al:Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty. Clin Endocrinol (Oxf) 44:515-523, 1996
18. Toretsky JA, Steinberg SM, Thakar M, et al: Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 92:2941-2947, 2001
19. Hixon ML, Gualberto A, Demers L, et al: Correlation of plasma levels of free insulin-like growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP-751, 871). J Clin Oncol 27:155s, 2009 (abstr 3539)
20. Cohen BD, Baker DA, Soderstrom C, et al: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063-2073, 2005 (Pubitemid 40471873)
21. Arteaga CL, Osborne CK: Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 49:6237-6241, 1989 (Pubitemid 20000915)
22. Gualberto A, Pollak M: Emerging role of insulin-like growth factor receptor inhibitors in oncology: Early clinical trial results and future directions. Oncogene 28:3009-3021, 2009